Genor Biopharma Holdings (HKG:6998) proposed to remove its auditor PricewaterhouseCoopers due to disagreements over audit documentation and financial reporting period for publishing results, according to a Tuesday filing with the Hong Kong bourse.
The company also proposed the appointment of Ernst & Young as the new auditor, subject to shareholder approval at an upcoming extraordinary general meeting on Feb. 19.
The pharmaceutical company's shares were almost 2% higher in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。